Multilocus genotypic association with vascular dementia by multifactor dimensionality reduction and entropy-based estimation

Plastic Surgical Nursing

Volumn 19, Issue 5, 2009, Pages 253-258

  Kim, Younyoung ^a   Park, Jungdae ^a   Lee, Chaeyoung ^a  

^a Soongsil University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR;

ARTICLE; BIOLOGICAL MODEL; ENTROPY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HUMAN; MULTIINFARCT DEMENTIA;

BRAIN-DERIVED NEUROTROPHIC FACTOR; DEMENTIA, VASCULAR; ENTROPY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LEUKEMIA INHIBITORY FACTOR; MODELS, GENETIC;

EID: 76249110022     PISSN: 07415206     EISSN: 15501841     Source Type: Journal    
DOI: 10.1097/YPG.0b013e32832ceebd     Document Type: Article

References (82)

1. American Psychiatric Association 1994. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington DC: American Psychiatric Association.
2. Jakulin A, Bratko I 2003. Analyzing attribute interactions. Lect Notes Artiff Intell 2838:229-240.
3. Jakulin A, Bratko I, Smrke D, Demsar J, Zupan B 2003. Attribute interactions in medical data analysis. Lect Notes Artif Intell 2780:229-238.
4. Kang Y, Na DL, Hahn S 1997. A validity study on the Korean mini-mental state examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 15:300-307.
5. Kim Y, Lee C 2006. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 37:2843-2845.
6. Kim Y, Nam YJ, Lee C 2005. Analysis of the SREBF2 gene as a genetic risk factor for vascular dementia. Am J Med Genet B 139:19-22.
7. Kim Y, Kim JH, Nam YJ, Kim YJ, Yu KH, Lee BC, et al. 2006a. sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia. Neurosci Lett 401:276-279.
8. Kim Y, Kim JH, Nam YJ, Kong M, Kim YJ, Yu KH, et al. 2006b. Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett 407:189-194.
9. Kim Y, Nam YJ, Lee C 2006c. Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. Am J Med Genet B 141:332-335.
10. McGill WJ 1954. Multivariate information transmission. Psychometrica 19:97-116.
11. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, et al. 2006. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241:252-261.
12. Motsinger AA, Ritchie MD 2006. Multifactor dimensionality reduction: an analysis strategy for modeling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2:318-328.
13. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. 2001. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69:138-147.
14. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. 1993. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260.
15. Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, Williams SM, et al. 2007. A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol 31:306-315.
16. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62.
17. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH 2003. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62.
18. Arinami T, Gao M, Hamaguchi H, Toru M 1997. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582.
19. Barratt DT, Coller JK, Somogyi AA 2006. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 141:323-331.
20. Basu S, Dasgupta PS 1999. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 44:916-921.
21. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574.
22. Bjorklund A, Dunnett SB 2007. Fifty years of dopamine research. Trends Neurosci 30:185-187.
23. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Ozkaragoz T, et al. 1993. Genetic predisposition in alcoholism: association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. Alcohol 10:59-67.
24. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. 2000. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 32 (Suppl: i-iv):1-112.
25. Breen G, Brown J, Maude S, Fox H, Collier D, Li T, et al. 1999. -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. Am J Med Genet 88:407-410.
26. Campa D, Zienolddiny S, Lind H, Ryberg D, Skaug V, Canzian F, Haugen A 2007. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. Lung Cancer 56:17-23.
27. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D 1996. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6:73-79.
28. Cravchik A, Sibley DR, Gejman PV 1996. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 271:26013-26017.
29. Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, et al. 2008. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 32:1722-1727.
30. Doehring A, von Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G, et al. (2008). Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dose requirements of methadone substitution. Pharmacogenet Genomics 19(6):407-414.
31. Drtilkova I, Sery O, Theiner P, Uhrova A, Zackova M, Balastikova B, Znojil V 2008. Clinical and molecular-genetic markers of ADHD in children. Neuro Endocrinol Lett 29:320-327.
32. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV 2003. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205-216.
33. Galvan A, Wichmann T 2008. Pathophysiology of Parkinsonism. Clin Neurophysiol 119:1459-1474.
34. Gaut BS, Long AD 2003. The lowdown on linkage disequilibrium. Plant Cell 15:1502-1506.
35. Gelernter J, O'Malley S, Risch N, Kranzler HR, Krystal J, Merikangas K, et al. 1991. No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA 266:1801-1807.
36. Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. 2005. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14:1633-1638.
37. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, et al. 1989. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45:778-785.
38. Grevle L, Guzey C, Hadidi H, Brennersted R, Idle JR, Aasly J 2000. Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease. Mov Disord 15:1070-1074.
39. Hardy GH 1908. Mendelian proportions in a mixed population. Science 28:49-50.
40. Hoenicka J, Aragues M, Rodriguez-Jimenez R, Ponce G, Martinez I, Rubio G, et al. 2006. C957 T DRD2 polymorphism is associated with schizophrenia in Spanish patients. Acta Psychiatr Scand 114:435-438.
41. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296.
42. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, et al. 2008. -141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. Psychiatr Genet 18:122-127.
43. Laruelle M, Gelernter J, Innis RB 1998. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 3:261-265.
44. Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J, et al. 2008. Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry 47:673-681.
45. Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S, et al. 2000. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96:592-598.
46. Lewontin RC 1964. The interaction of selection and linkage. I. General Considerations. Heterotic models. Genetics 49:49-67.
47. Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V 2008. Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 100:302-307.
48. Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R, et al. 2006. DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenet Genomics 16:901-910.
49. Neville MJ, Johnstone EC, Walton RT 2004. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23:540-545.
50. Noble EP 2000. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 15:79-89.
51. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ 1991. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48:648-654.
52. Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, et al. 1993. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 33:271-285.
53. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, et al. 1994a. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 42:257-260.
54. Noble EP, Syndulko K, Fitch RJ, Ritchie T, Bohlman MC, Guth P, et al. 1994b. D2 dopamine receptor TaqI A alleles in medically ill alcoholic and nonalcoholic patients. Alcohol Alcohol 29:729-744.
55. Noble EP, Zhang X, Ritchie TL, Sparkes RS 2000. Haplotypes at the DRD2 locus and severe alcoholism. Am J Med Genet 96:622-631.
56. Nyren P, Lundin A 1985. Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis. Anal Biochem 151:504-509.
57. Oliveri RL, Annesi G, Zappia M, Civitelli D, De Marco EV, Pasqua AA, et al. 2000. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord 15:127-131.
58. Parsian A, Cloninger CR, Zhang ZH 2000. Functional variant in the DRD2 receptor promoter region and subtypes of alcoholism. Am J Med Genet 96:407-411.
59. Parsons MJ, Mata I, Beperet M, Iribarren-Iriso F, Arroyo B, Sainz R, et al. 2007. A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 17:159-163.
60. Perez de los Cobos J, Baiget M, Trujols J, Sinol N, Volpini V, Banuls E, et al. 2007. Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: a case control study. Behav Brain Funct 3:25.
61. Picetti R, Saiardi A, Abdel Samad T, Bozzi Y, Baik JH, Borrelli E 1997. Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol 11:121-142.
62. Pierce RC, Kumaresan V 2006. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215-238.
63. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3:256-260.
64. Rodriguez-Jimenez R, Avila C, Ponce G, Ibanez MI, Rubio G, Jimenez-Arriero MA, et al. 2006. The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patients. Eur Psychiatry 21:66-69.
65. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P 1996. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242:84-89.
66. Ronaghi M, Uhlen M, Nyren P 1998. A sequencing method based on real-time pyrophosphate. Science 281:363-365.
67. Sander T, Ladehoff M, Samochowiec J, Finckh U, Rommelspacher H, Schmidt LG 1999. Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population. Alcohol Clin Exp Res 23:578-581.
68. Schultz W 2007. Behavioral dopamine signals. Trends Neurosci 30:203-210.
69. Sery O, Drtilkova I, Theiner P, Pitelova R, Staif R, Znojil V, et al. 2006. Polymorphism of DRD2 gene and ADHD. Neuro Endocrinol Lett 27:236-240.
70. Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S 1998. Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 8:125-128.
71. Smidt MP, Smits SM, Burbach JP 2003. Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur J Pharmacol 480:75-88.
72. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, et al. 1998. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358-363.
73. Stephens M, Donnelly P 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
74. Stephens M, Smith NJ, Donnelly P 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
75. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. 1997. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484.
76. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. 2000. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203.
77. Wise RA 2004. Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.
78. Woldman I, Reither H, Kattinger A, Hornykiewicz O, Pifl C 2005. Dopamine inhibits cell growth and cell cycle by blocking ribonucleotide reductase. Neuropharmacology 48:525-537.
79. Worrel JA, Marken PA, Beckman SE, Ruehter VL 2000. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57:238-255.
80. Yamamoto M, Schapira AH 2008. Dopamine agonists in Parkinson's disease. Expert Rev Neurother 8:671-677.
81. Young RM, Lawford BR, Nutting A, Noble EP 2004. Advances in molecular genetics and the prevention and treatment of substance misuse: implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 29:1275-1294.
82. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. 2007. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A 104:20552-20557.